Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from
- PDF / 1,187,717 Bytes
- 4 Pages / 595.276 x 790.866 pts Page_size
- 68 Downloads / 171 Views
ETTER TO THE EDITOR
Experimental Hematology & Oncology Open Access
Clinical characteristics and outcome of SARS‑CoV‑2 infection in admitted patients with chronic lymphocytic leukemia from a single European country Ana Muntañola1, Guillermo Villacampa2,3, José Ángel Hernández‑Rivas4, Rosalía Alonso5, Fátima Mirás6, Santiago Osorio7, Mónica Baile8, Patricia Baltasar9, Javier López Jiménez10, Ines Hernandez‑Rodriguez11, Susana Valenciano12, Ana Alfayate13, Eva Gimeno14, Abelardo Bárez15, Ana C. Oliveira16, Rosalía Riaza17, Pilar Romero18, Julio Delgado19, Lucrecia Yáñez20, Amaya Zabalza21, Ana Torres22, Mª Isabel Gómez‑Roncero23, Marta Crespo24, Raúl Córdoba25, Juan José Mateos‑Mazón26, Sonia Pérez27, Rafael Andreu28, Jorge Labrador29, Mª Elena Ruiz30, César Andrés Velasquez31, Mª José Terol32, Raquel Santiago33, Mª Jesús Vidal34, Fiz Campoy García35, Lucía Villalón36, Begoña S. Muiña37, Joan Alfons Soler38, Cristina Seri39, Mª José Sánchez40, Amalia Cuesta41, Rafael Ramos42, Adrián Sánchez‑Montalvá24, Isabel Ruiz‑Camps24, Marcos González8, Pau Abrisqueta24* and Francesc Bosch24 on behalf of of the GELLC (Grupo Español de Leucemia Linfática Crónica)
Letter to the editor Spain has been one the most affected countries by the severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), the causative agent of coronavirus disease 2019 (COVID-19) pandemic [1, 2]. Patients with chronic lymphocytic leukemia (CLL) could be at risk of more severe COVID-19 clinical forms [3] since they often carry immune perturbations aggravated by treatments used for the disease itself [4]. Two major series on patients with COVID-19 and CLL encompassing different countries and health systems reported heterogeneous factors related to the outcome [5, 6]. Herein, we are presenting the largest series of CLL patients with proved COVID-19 from a single country and Health system.
*Correspondence: [email protected] 24 Department of Hematology, Vall d’Hebron Barcelona Hospital Campus, Passeig de la Vall d’Hebron, 119‑129, 08035 Barcelona, Spain Full list of author information is available at the end of the article
We identified 165 patients with CLL and COVID-19 across 40 Spanish centers (Additional file 1: Table S1 and S2) between March 1, 2020 and May 31, 2020. In summary, at the time of infection median age was 73 years, 27% were younger than 65, and 40% had comorbidities (CIRS ≥ 6). Eighty-five patients (52%) were in watch & wait (W&W), 34 (21%) had been previously treated, whereas 46 patients (28%) were currently on CLL treatment, mainly with BTK inhibitors (BTKi) (n = 34) and venetoclax (n = 7). Increased CRP (> 0.3 mg/dL) was detected in 27.8%, increased D-dimer (> 500 mg/mL) in 70%, ferritin > 400 mg/mL in 74%, and elevated IL-6 in 88% of patients in whom it was assessed. Among these inflammatory parameters, ferritin and D-dimer were significantly lower in patients receiving BTKi at the time of COVID-19 compared to the others (Additional file 1: Fig. S1). 92% of the patients required hospital admission, with 31% requiring intensive ma
Data Loading...
